Evaluation of the Temporal Muscle Thickness as an Independent Prognostic Biomarker in Patients with Primary Central Nervous System Lymphoma.
overall survival
primary central nervous system lymphoma
prognostic parameter
sarcopenia
temporal muscle thickness
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
12
12
2020
revised:
19
01
2021
accepted:
20
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
In this study, we assessed the prognostic relevance of temporal muscle thickness (TMT), likely reflecting patient's frailty, in patients with primary central nervous system lymphoma (PCNSL). In 128 newly diagnosed PCNSL patients TMT was analyzed on cranial magnetic resonance images. Predefined sex-specific TMT cutoff values were used to categorize the patient cohort. Survival analyses, using a log-rank test as well as Cox models adjusted for further prognostic parameters, were performed. The risk of death was significantly increased for PCNSL patients with reduced muscle thickness (hazard ratio of 3.189, 95% CI: 2-097-4.848,
Identifiants
pubmed: 33540564
pii: cancers13030566
doi: 10.3390/cancers13030566
pmc: PMC7867149
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
PLoS One. 2012;7(4):e34444
pubmed: 22509305
J Gerontol A Biol Sci Med Sci. 2018 Aug 10;73(9):1199-1204
pubmed: 29300839
PLoS One. 2018 Nov 29;13(11):e0207849
pubmed: 30496307
J Neurooncol. 2018 Oct;140(1):173-178
pubmed: 30008154
Eur Radiol. 2017 Aug;27(8):3167-3173
pubmed: 28050694
J Neurosurg. 2014 Jan;120(1):24-30
pubmed: 24160479
Eur Radiol. 2020 Nov 17;:
pubmed: 33201284
Support Care Cancer. 1999 Sep;7(5):332-5
pubmed: 10483818
J Neurooncol. 2009 Dec;95(3):401-411
pubmed: 19562257
Eur Radiol. 2016 May;26(5):1359-67
pubmed: 26334504
Age Ageing. 2016 Sep;45(5):602-8
pubmed: 27126327
J Cancer Res Clin Oncol. 2021 Mar;147(3):901-909
pubmed: 32929611
Eur J Cancer. 2016 Apr;57:58-67
pubmed: 26882087
Asia Pac J Clin Oncol. 2020 Oct;16(5):e223-e227
pubmed: 32762134
J Clin Oncol. 2003 Jan 15;21(2):266-72
pubmed: 12525518
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36
pubmed: 27066316
Osteoporos Int. 2015 Dec;26(12):2793-802
pubmed: 26068298
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):615-20
pubmed: 9635710
Neuro Oncol. 2019 Dec 17;21(12):1587-1594
pubmed: 31369680
Geriatr Gerontol Int. 2019 Feb;19(2):135-140
pubmed: 30689287
J Clin Oncol. 2013 Sep 1;31(25):3061-8
pubmed: 23569323
J Nutr Health Aging. 2018;22(7):766-773
pubmed: 30080217
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
Blood. 2015 Feb 26;125(9):1403-10
pubmed: 25568347
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Eur J Orthod. 2009 Dec;31(6):596-612
pubmed: 19656804
Clin Neurol Neurosurg. 2019 Nov;186:105535
pubmed: 31569058
J Clin Med. 2020 Apr 28;9(5):
pubmed: 32354003